Advertisement

Topics

NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in ...

03:00 EST 13 Nov 2017 | BioMedReports - Blog

NousCom combined its vectored genetic vaccine encoding multiple cancer neoantigens, capable of inducing potent and broad T cell responses, with NKTR-214, designed to expand the

Related Biotechnology, Pharmaceutical and Healthcare News

Read more...

Original Article: NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in ...

NEXT ARTICLE

More From BioPortfolio on "NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in ..."

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.